Devices › Marker, radiographic, implantable
Device brand name · Marker radiographic implantable
Biozorb: medical device reports filed with FDA
673 reports name it, 2021–2026. Manufacturer given most often on reports: Hologic. Product code NEU.
- 673
- device reports naming the brand
- 0% of all MAUDE reports · about 128 a year
- 151
- reports, 12 months to August 2026
- 356 in the 12 months before
- 2.2%
- classified as malfunction
- 35.2% across the product code
- 0%
- classified as death, as reported
- 0 reports · not verified by FDA
673 medical device reports received by FDA name the brand "Biozorb" (marker radiographic implantable); the manufacturer given most often on reports is Hologic; received from April 2021 to August 2026. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.
151 reports arrived in the 12 months to August 2026, down 58% from 356 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (97.8%) and malfunction (2.2%); across all marker, radiographic, implantable reports (product code NEU) death is recorded in 0.1% and malfunction in 35.2%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are migration (4.2%), fracture (3.3%) and migration or expulsion of device (3.1%). The patient problems coded most often are breast discomfort/pain, swelling/ edema and bacterial infection. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 1,870 reports carrying product code NEU. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Migrationthe device moved from where it was placed | 28 | 4.2% | 3.5% |
| Fracturea broken bone | 22 | 3.3% | 1.3% |
| Migration or expulsion of device | 21 | 3.1% | 3% |
| Breakthe device broke | 7 | 1% | 4.9% |
| Insufficient device problem information | 7 | 1% | 1.7% |
| Unintended movement | 4 | 0.6% | 0.2% |
| Patient device interaction problem | 3 | 0.4% | 1% |
| Biocompatibility | 2 | 0.3% | 0.1% |
| Detachment of device or device componentpart of the device came off | 2 | 0.3% | 2.2% |
| Device appears to trigger rejection | 2 | 0.3% | 0.4% |
| Material integrity problema problem with the device material | 2 | 0.3% | 0.1% |
| Nonstandard device | 2 | 0.3% | 0.4% |
| Crackthe device cracked | 1 | 0.1% | 0% |
| Defective devicethe device was defective | 1 | 0.1% | 0.3% |
| Material disintegration | 1 | 0.1% | 0% |
| Material fragmentation | 1 | 0.1% | 2% |
| Material protrusion/extrusion | 1 | 0.1% | 0.2% |
| Patient-device incompatibilitythe device did not suit the patient | 1 | 0.1% | 3.2% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Breast discomfort/pain | 455 | 67.6% |
| Swelling/ edema | 144 | 21.4% |
| Bacterial infectiona bacterial infection | 139 | 20.7% |
| Erythemaskin redness | 124 | 18.4% |
| Seromaa collection of fluid under the skin | 119 | 17.7% |
| Breast mass | 100 | 14.9% |
| Deformity/ disfigurement | 74 | 11% |
| Sleep dysfunction | 67 | 10% |
| Itching sensation | 44 | 6.5% |
| Scar tissue | 38 | 5.6% |
| Necrosisdeath of tissue | 37 | 5.5% |
| Hematomaa collection of blood under the skin or in tissue | 36 | 5.3% |
| Abscessa collection of pus | 28 | 4.2% |
| Rashskin rash | 28 | 4.2% |
| Erosion | 26 | 3.9% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Biozorb | Product code NEU | All MAUDE reports |
|---|---|---|---|
| Reports | 673 | 1,870 | 26,136,888 |
| Share of that pool | — | 36% | 0% |
| Classified as death, per 1,000 reports | 0 | 1 | 9 |
| Classified as injury | 97.8% | 63% | 36.2% |
| Classified as malfunction | 2.2% | 35.2% | 62.3% |
| Filed by the manufacturer | 94.1% | 84.8% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code NEU
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| 8g Mammomark Breast Marker | 177 | 0 | 0% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Biozorb reports
How many FDA reports name Biozorb?
673 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 151 in the latest 12 months.
What kinds of events are reported?
injury (97.8%) and malfunction (2.2%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
migration (4.2%), fracture (3.3%), migration or expulsion of device (3.1%), break (1%) and insufficient device problem information (1%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (94.1%) and voluntary reports (5.8%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Biozorb was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.